Orticumab
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL) . Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL) . Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].
Product Specifications
CAS Number
[1314241-10-5]
Product Name Alternative
MLDL1278A
UNSPSC
12352203
Target
LDLR
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/orticumab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Orticumab]
Molecular Weight
(143.68 kDa)
References & Citations
[1]Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. |[2]Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
422239 1 mg
(2Z) -2-[ (4E) -4-[ (2E) -1-Methyl-3- (2,6,6-trimethyl-1-cyclohexen-1-yl) -2-propen-1-ylidene]-2-cyclohepten-1-ylidene]-acetaldehyde
Ask
View Details